GitLab isn't simply riding the AI boom—it helps build it. With repeated insider buying by CEO William Staples, a $400 million buyback authorization, strong free cash flow, and an integrated DevSecOps platform, GitLab may represent one of enterprise software's more overlooked long-term opportunities.

Read entire article

When FUNanc1al first highlighted Absci around $4.18, the thesis centered on insider buying and an overlooked AI-biotech platform. Today the stock has nearly tripled, Eli Lilly has invested $100 million, institutions own over 80%, and another director is buying shares. Here's why the story may still be in its early innings.

Read entire article

PayPal has lost more than 85% of its value since 2021, yet it continues to grow revenue, generate billions in free cash flow, and aggressively repurchase shares. Has Wall Street become too pessimistic, or is PYPL a classic value trap? We examine the bull case, the risks, and what could reignite growth.

Read entire article

RH isn't just selling luxury furniture anymore—it's trying to redefine luxury living. With a major insider purchase, elevated short interest, ambitious global expansion, and Wall Street split on the outlook, RH may be one of today's most intriguing turnaround stories.

Read entire article

Autodesk isn't trying to beat AI—it may be one of the companies best positioned to integrate it. With executives buying shares, free cash flow soaring 58%, and a surprisingly attractive PEG ratio, ADSK deserves another look.

Read entire article

Wall Street says AI threatens Adobe. The numbers tell a different story. Revenue keeps hitting records, AI recurring revenue has tripled, valuation has collapsed to multi-year lows, and Eli Lilly CEO David Ricks just invested another $1.9 million of his own money. Here's why Adobe may deserve another look.

Read entire article

CarMax isn't a flashy AI stock—but it may be one of the more interesting turnaround stories in today's market. New CEO Keith Barr just invested nearly $500,000 of his own money, institutions control over 112% of the float, and valuation appears unusually attractive on a PEG basis. Here's why we think investors should take a closer look.

Read entire article

Powerlaw isn't simply another investment company—it's a gateway into some of the world's most valuable private technology businesses. With insider buying near NAV and holdings including SpaceX, OpenAI, Kalshi, Stripe and Anthropic, investors must answer one key question: are they buying today's NAV, or tomorrow's?

Read entire article

Abbott Laboratories may not be flashy, but the healthcare giant combines insider buying, a growing oncology diagnostics platform, the dominant FreeStyle Libre franchise, and more than a century of dividend payments. With shares trading near 16x forward earnings, investors may be looking at a classic Growth at a Reasonable Price opportunity.

Read entire article

Mission Produce's directors recently deployed nearly $7.9 million of personal capital into AVO shares. Combined with the Calavo acquisition, a fresh $100 million buyback, and a move into higher-margin prepared foods, the avocado giant may be entering a new chapter.

Read entire article